INTRODUCTION AND AIMS:
Tacrolimus (Tac), mycophenolic acid (MPA) and prednisolone are major immunosuppressive drugs after renal transplantation (RTx) and Tac is often considered as the mainstay of the RTx therapy. There are reports in the literature regarding the use of Tac in bronchiolitis obliterans after lung transplation and interstitial lung diseases related to connective tissue diseases. Also MPA is reported to be effective in scleroderma induced interstitial lung disease even in lower doses. We herein present the preliminary results of follow -up the lung functions of RTx recipients with no underlying lung disease. METHODS: We collected data of 51 RTx patients, 19 Female and 32 Male, ages varying between 23-67 years (mean age: 49.76 years) between January 2015 and January 2018 receiving standart immunosuppressive therapy. Those data included spirometry, CO diffusion tests, Tac dosing regimen and serum Tac levels. Spirometry were performed in 3 periods: before RTx (baseline), 3 to 9 months after RTx and first year post -RTx. RESULTS: The mean percentage predicted baseline forced vital capacity (FVC) was 80.2 % 6 1.5 standart deviation (SD). The mean percentage predicted 1 year post -RTx was 92.3 % 6 19 SD. The difference between the results were statistically significant (p¼ 0.001) . The mean percentage predicted baseline forced expiratory volume in 1 second (FEV1) was 78.2 % 6 0.7 SD. The mean percentage predicted FEV1 one year postRTx was 86.3 % 6 17 SD. The difference between those FEV 1 levels were also statistically significant (p¼ 0.031). The mean percentage predicted 3 to 9 months after RTx FEV1 was 93.8 % 6 19.3 SD. The mean percentage predicted 1 year post -RTx FEV 1 was 86.3 %6 16.5 SD. When those results were compared, the difference was statistically significant (p¼ 0.018). There were no statistically significant difference between CO diffusion test results obtained at the same time periods as spirometry. CONCLUSIONS: Our findings suggest that, with appropriate immunosuppressive regimens and proper follow -up, lung functions are preserved and even improved in RTx recipients. As there is an expected decrease in FEV 1 levels in elderly patients, it is especially important that we have seen an increase in FEV 1 levels in a RTx patient group consisting of relatively old individuals. transplantation (ABOiKT) in now increasing used in developing country to increase living donor kidney transplantation as ABO incompatibility has been considered as an important immunological barrier for renal transplantation is in initial stages. METHODS: We report prospective single center results of ABOiKT in 28 living-related donor kidney transplantation (LDKT) patients during December 2014 to November 2017. The study was approved by institutional review board and ethical committee. We describe patient survival, graft survival, rejection rate and cost analysis. Each donor-recipient pairs were given education, awareness and counseling about risk and benefits of ABOiKT, kidney paired donation and DDKT. ABOiKT was performed after written informed consent of donor-recipient pairs. Easy to match pairs (A donor and B recipient; B donor and A recipient) and sensitized pairs preferred for KPD over ABOiKT and desensitization protocol. Preconditioning protocol consisted plasmapheresis, low-dose intravenous immunoglobulin (IVIG) (100mg/kg), and low-dose rituximab (200 mg) and maintenance immunosuppression consisted of tacrolimus, mycophenolate sodium, and prednisolone. All patients had negative lymphocyte, flow cross match and donor specific antibody before transplantation.A pretransplantation isoagglutinin titer of 1:4 was considered acceptable for transplantation. Post-transplant plasmapheresis was done when isoagglutinin titer of 1:16 and biopsy proven antibody mediated rejection. RESULTS: Mean age of patients was 28 years and 27 were males. Mean age of donors was 43 years and 2 were males. The donor relation was parents (n¼21) , Spouse (n¼5) and siblings (n¼2). Mean HLA match ( A,B,DRB1 and A,B,DR B1) was 2.8 .Donorrecepient blood group was A to O (n¼8) ,B to O ( n¼8) , AB to O (n¼6) A to B (n¼2) B to A ( n¼2). Median ABO titers were 1:32 (1:4 -1:124).Patient survival was 89%(n¼25) ,death censored graft survival was 92%(n¼26), mean serum creatinine(mg/dl)was 1.2 and BPAR was 17%(n¼5) respectively, over mean follow-up of 16.4 months. Infections were observed in 28% (n¼8) patients.C CONCLUSIONS: We conclude that short-term outcome of ABOi KT is acceptable. ABOiKT should be promoted in developing countries to expand the donor pool. There is no established treatment of FSGS after renal transplantation. The therapy may include among others plasmapheresis, anty-CD20 antibody (rituximab), immunoadsorption, cyclosporine, metyloprednisolone. The aim of our study was to evaluate the therapy of rituximab in recurrent and de novo FSGS after renal transplantation. METHODS: We analyzed 7 patients after transplantation who developed FSGS which was diagnosed in a biopsy for cause. FSGS was the cause of own kidney insufficiency in 5 patients and 2 patients developed FSGS de novo. The treatment consisted of Rituximab and plasmapheresis. One patient received Rituximab as induction of immunosupressive therapy in day 0 and 7 after second kidney transplantation because of recurrence of FSGS in the first transplant. Response to the treatment was evaluated by measuring B-cell depletion by flow-cytometry. RESULTS: The mean time after transplantation to transplant biopsy was 19,7 months. The mean creatinine level at the time of rituximab treatment was 1,70mg/dl. Mean proteinuria was 4,55g/24h. Mean protein level was 5,88g/dl and mean albumin level was 3,23g/dl. Stable renal function was observed in 5 patients after 12 months. Mean creatinine was 1,27mg/dl. The decreasing proteinuria was observed in 4 patients. Mean proteinuria was 0,7g/24h. Two patients required dialysis in the first year. Severe infections (recurrent CMV infections, sepsis) appeared in the same 2 patients. This patients required graftectomy. CONCLUSIONS: The treatment of Rituximab after renal transplantation was effective in 5(62,5%) patients. Severe infections may appear after Rituximab therapy.
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